FDA Drugs recall ·

Opdualag (nivolumab and relatlimab-rmbw) injection… recall

Recall number
D-0097-2026
Date
(initiated October 21, 2025)
Company / brand
Bristol-Myers Squibb Company
1 Squibb Dr, New Brunswick, NJ, United States
Category
Drugs › Class II
Classification
Class II
Status
Ongoing
Units affected
12,778 total vials
Hazard tags
Sterility
Initiated by
Voluntary: Firm initiated

Read the official FDA notice ↗

Product

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Why was it recalled?

Lack of Assurance of Sterility.

What should you do?

FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.

Product codes & lot numbers

Lot: 033A23B, Expiry: 4/30/2026

Distribution

Nationwide in the USA

What does Class II mean?

Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.

Source: FDA (drugs), recall D-0097-2026. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.